

A

Customer No. 000959

Case Docket No. UMV-1584

THE ASSISTANT COMMISSIONER FOR PATENTS
Box Patent Application
Washington, D.C. 20231

"Express Mail" Mailing Label Number EL373205459USDate of Deposit July 20, 1999

I hereby certify that this transmittal letter and the papers referred to as being enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Nelson Barros

Signature

Nelson Barros

Please Print Name of Person Signing

Sir:

Transmitted herewith for filing is the patent application of

Inventor(s): Randal J. Kaufman; Witoon Tirasophon; and Ajith A. Welihinda

For: IRE1P, NOVEL MAMMALIAN PROTEIN, AND GENE ENCODING SAME

Enclosed are:

- ☐ This is a request for filing a ☐ continuation ☐ divisional application under 37 CFR 1.53(b), of pending prior application serial no. _____ filed on _____ entitled _____.
- ☒ This application claims priority to U.S. Serial No. 60/093,526 filed on July 21, 1998.
- ☒ 29 pages of specification, 3 pages of claims, 1 pages of abstract.
- ☒ 9 sheets of drawings.
- ☐ A Declaration, Petition and Power of Attorney.
- ☐ An assignment of the invention to _____. A recordation form cover sheet (Form PTO 1595) is also enclosed.
- ☐ A verified statement to establish small entity status under 37 C.F.R. 1.9 and 37 C.F.R. 1.27.
- ☐ Other _____

The filing fee has been calculated as shown below:

	(Col. 1)	(Col. 2)
FOR:	NO. FILED	NO. EXTRA
BASIC FEE	////////////////////	
TOTAL CLAIMS	30 - 20	= 10
INDEP. CLAIMS	6 - 3	= 3
<input checked="" type="checkbox"/> MULTIPLE DEPENDENT CLAIMS PRESENTED		

* If the difference in Col. 2 is less than zero,
enter "0" in Col. 2.

SMALL ENTITY	
RATE	FEE
////////	\$ 380
x 9=	\$ 90
x 39	\$ 117
+130	\$ 130
TOTAL	\$717.00

OTHER THAN SMALL ENTITY	
RATE	FEE
////////	\$
x 18=	\$
x 78	\$
+260	\$
TOTAL	0

- ☐ Please charge my Deposit Account No. 12-0080 in the amount of \$.
A duplicate copy of this sheet is enclosed.
- ☐ A check in the amount of \$ to cover the filing fee is enclosed.
- ☐ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 12-0080.
A duplicate copy of this sheet is enclosed.

07/20/99
jc525 U.S. PTO

jc511 U.S. PTO
09/357273
07/20/99

09/357273 07/20/99

- ☐ Any additional filing fees required under 37 C.F.R. 1.16.
- ☐ Any patent application processing fees under 37 C.F.R. 1.17.
- ☐ The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No. 12-0080.
A duplicate copy of this sheet is enclosed.
- ☐ Any patent application processing fees under 37 C.F.R. 1.17.
- ☐ The issue fee set in 37 C.F.R. 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).
- ☐ Any filing fees under 37 C.F.R. 1.16 for presentation of extra claims.
- ☐ A check in the amount of \$ _____ to cover the recording of assignment documents is also enclosed.
- ☒ Address all future communications (May only be completed by applicant, or attorney or agent of record) to DeAnn F. Smith at **Customer Number: 000959** whose address is:

Lahive & Cockfield, LLP
28 State Street
Boston, Massachusetts 02109

Date: July 20, 1999

LAHIVE & COCKFIELD, LLP
Attorneys at Law

By DeAnn F. Smith
DeAnn F. Smith
Reg. No. 36,683
28 State Street
Boston, MA 02109
(617) 227-7400
Telecopier (617) 742-4214

660220 E 224566

Ire1p, A NOVEL MAMMALIAN PROTEIN AND GENE ENCODING SAME

RELATED APPLICATIONS

5 This application claims priority to U.S. Serial No. 60/093,526, filed on July 21, 1998, the contents of which are incorporated herein by reference.

FIELD OF THE INVENTION

 The present invention relates generally to novel polynucleotides and the proteins
10 encoded thereby and more particularly, to polynucleotides encoding a novel mammalian bifunctional protein kinase/endoribonuclease (Ire1p), and therapeutic, diagnostic and research methods employing same.

BACKGROUND OF THE INVENTION

 The endoplasmic reticulum (ER) is an organelle specialized for protein folding and
15 assembly of membrane proteins and of proteins destined for trafficking to lysosomes and the extracellular space. Newly synthesized lysosomal, secretory, and membrane proteins are translocated into the lumen of the ER that provides an oxidizing environment and contains a multitude of ER resident proteins that facilitate the folding process (reviewed by Gething and Sambrook, *Nature* 355:34-44 (1992); Hartl, F.U., *Nature* 381:571-579
20 (1996)). The transcription of many of the genes encoding ER resident proteins, such as BiP (immunoglobulin binding protein or GRP78), is upregulated in response to glucose deprivation (Lee, A.S., *Trends Biochem. Sci.* 12:20-30 (1987)), in response to conditions that disrupt protein folding in the ER, and in response to the presence of unfolded or unassembled proteins in the ER. Lee, A.S., *Trends Biochem. Sci.* 12:20-30 (1987);
25 Kozutsumi, Y. et al., *Nature* 332:462-464 (1988); Dorner, A.J. et al., *J. Biol.Chem.* 264:20602-20607 (1989). Thus, an unfolded protein response (UPR) exists in cells that detects unfolded protein in the ER lumen to transduce a signal(s) across the ER membrane to activate transcription of selective genes in the nucleus. Kozutsumi, Y. et al., *Nature* 332:462-464 (1988).

30 Although little is known about the mechanism of the UPR signal transduction pathway in higher eukaryotes, studies from the budding yeast, *Saccharomyces cerevisiae*, demonstrate the existence of a complex unique signaling pathway between these two organelles. Mori, K. et al., *EMBO J.* 11:2583-2593 (1992). Characterization of the promoters of the genes encoding ER resident proteins e.g. *KAR2* (yeast BiP),
35 demonstrated that they share a highly conserved *cis*-acting regulatory Unfolded Protein Responsive Element (UPRE), that is necessary and sufficient to mediate the response to

unfolded protein in the ER. Mori, K. et al., *Cell* 74:743-756 (1993); Cox, J.S. et al., *Cell* 73:1197-1206 (1993). By using genetic approaches, Ire1p/Ern1p, an ER type 1 transmembrane protein that contains a Ser/Thr protein kinase domain in its carboxy terminus, was identified as the UPR proximal sensor that monitors the status of unfolded protein inside the ER lumen. Cox, J.S. et al., *Cell* 73:1197-1206 (1993); Mori, K. et al., *Cell* 74:743-756 (1993). Ire1p was originally identified as a gene required for inositol prototrophy in *S. cerevisiae*. Nikawa, J. et al., *Mol. Microbiol.* 6:1441-1446 (1992). The kinase activity of Ire1p is essential to transmit the UPR signal from the ER to induce specific gene transcription in the nucleus. Mori, K. et al., *Cell* 74:743-756 (1993); Shamu, C.E. et al., *EMBO J.* 15:3028-3039 (1996). Cox and Walter (*J. Biol. Chem.* 264:20602-20607 (1996)) subsequently reported that Ire1p directly regulated biosynthesis of Hac1p, a transcription factor that binds specifically to the UPRE. Recent studies demonstrate that *HAC1* mRNA is synthesized as a precursor that is inefficiently translated. Upon activation of the UPR, Ire1p elicits an endonuclease activity that specifically cleaves an intron from *HAC1* mRNA. Subsequently, the tRNA ligase Rlg1p is required to splice together the 5' and 3' cleaved fragments to yield a product that is efficiently translated. Cox, J.S. et al., *J. Biol. Chem.* 264:20602-20607 (1996); Sidrauski, K. et al., *Cell* 90:1031-1039 (1997); Kawahara, T. et al., *Mol. Biol. Cell* 8:1845-1862 (1997); Chapman, R.E. et al., *Curr. Biol.* 7:850-859 (1997)). The increased level of Hac1p leads to the transcriptional activation of genes containing a UPRE.

While the molecular mechanisms signaling the yeast UPR are well characterized, the mechanisms signaling the UPR in mammalian cells remain elusive. A conserved promoter region, the glucose-regulated core sequence, in several mammalian genes encoding for ER proteins was identified as a potential *cis*-acting regulatory element equivalent to the yeast UPRE. Resendez, E.J. et al., *Mol. Cell . Biol.* 8:4579-4584 (1988). Despite the sequence similarity between the mammalian glucose-regulated core sequence and the *S. cerevisiae* UPRE, no single element in this promoter region appears necessary and sufficient to mediate transcriptional induction as described for the UPRE in yeast cells. In addition, although transcriptional activation in response to conditions that disrupt protein folding in the ER correlates with changes in activities of protein kinases and phosphatases (Resendez. E. et al., *J. Cell Biol.* 103:2145-2152 (1986); Koong et al. 1994; Cao, X. et al., *J. Biol. Chem.* 270:494-502 (1995); Chen, K. et al., *J. Biol. Chem.* 273:749-755 (1998)), a signaling molecule that responds to unfolded protein in the ER to induce transcription of the ER protein chaperone genes has not been identified.

It would thus be desirable to provide a mammalian signaling molecule that responds to unfolded protein in the ER to induce transcription of the ER protein chaperone genes. It would also be desirable to identify and characterize the human gene product that is equivalent to Ire1p of *S. cerevisiae* and functions as a proximal sensor for the UPR
5 in mammalian cells. It would further be desirable to provide a method for protecting cells from the stressful condition of unfolded protein in the ER.

SUMMARY OF THE INVENTION

A novel polynucleotide encoding a mammalian bifunctional protein kinase\endoribonuclease referred to herein as hlre1p, is provided. hlre1p is expressed in
10 the endoplasmic reticulum (ER) and upregulates the transcription of genes encoding ER protein chaperones, such as, but not limited to, glucose-related proteins (GRP's).

hlre1p is a type 1 transmembrane protein containing a cytoplasmic domain that is highly conserved to the yeast counterpart having a Ser/Thr protein kinase domain and a domain homologous to RNase L. However, the luminal domain has extensively diverged
15 from the yeast gene product. hlre1p expressed in mammalian cells displays intrinsic autophosphorylation activity and an endoribonuclease activity that cleaves the 5' splice site of yeast *HAC1* mRNA, a substrate for the endoribonuclease activity of yeast Ire1p.

Over-expressed hlre1p is localized to the ER with particular concentration around the nuclear envelope and some co-localization with the nuclear pore complex. Expression
20 of *hIRE1* mRNA is autoregulated through a process that requires a functional hlre1p kinase activity. Over-expression of wild-type hlre1p constitutively activates a reporter gene under transcriptional control of the rat BiP promoter, whereas expression of a catalytically inactive hlre1p acts in a *trans*-dominant negative manner to prevent transcriptional activation of the BiP promoter in response to ER stress induced by
25 inhibition of N-linked glycosylation.

Signaling mechanism(s) by which cells respond to ER stress have important therapeutic implications. Expression of Ire1p results in induction of GRPs, including BiP and GRP94, protecting cells from death induced by calcium release from the ER (Morris, J.A. et al., *J. Biol. Chem.* 272:4327-4334 (1997)), oxidative stress (Gomer, C.J. et al.,
30 *Cancer Res.* 51:6574-6579 (1991)), and anti-cancer treatments such as adriamycin and topoisomerase inhibitors. Shen, J. et al., *Proc. Natl. Acad. Sci. USA* 84:3278-3282 (1987); Hughes, C.S. et al., *Cancer Res.* 49:4452-4454 (1989). Conversely, inhibiting expression of Ire1p inhibits induction of GRP and increases sensitivity of a cell to death in response to calcium release from the ER (Li, X.A. et al., *Mol. Cell. Biol.* 11:3446-3453

(1991); Li, X.A. et al., *J. Cell Physiol.* 153:575-582 (1992)), oxidative stress (Gomer, C.J. et al., *Cancer Res.* 51:6574-6579 (1991)), hypoxia (Koong et al. 1994), and T cell mediated cytotoxicity. Sugawara, S. et al., *Cancer Res.* 53:6061-6005 (1993). Thus, methods for protecting cells from death by increasing expression of *hIRE1*, as well as methods for increasing sensitivity of a cell to death by inhibiting expression of *hIRE1*, are provided.

Additional objects, advantages, and features of the present invention will become apparent from the following description and appended claims, taken in conjunction with the accompanying drawings.

10 BRIEF DESCRIPTION OF THE DRAWINGS

The various advantages of the present invention will become apparent to one skilled in the art by reading the following specification and subjoined claims and by referencing the following drawings.

Figure 1. Structure and amino acid sequence analysis of *hlre1p*.

15 (A) *Alignment and restriction map of overlapping complementary DNAs encoding human Ire1p.* RH3 was the primary probe used to screen a human fetal liver cDNA library to obtain cDNA clones 3-1-1, 3-1.2, 8-1, 9-1, 13-1 and 17-1. F14 was a 5' RACE-PCR product amplified from RNA isolated from the human hepatoma cell line HepG2. An open box represents the predicted open reading frame coding for *hlre1p*.

20 (B) *Domain organization of hlre1p.* Solid box, a potential signal sequence; □, potential N-linked glycosylation site; TM, a putative transmembrane region; Linker, a region having not homology to known proteins; S/T kinase, catalytic domain of Ser/Thr protein kinase; RNase L, a domain having high homology to 2-5 oligo-A-dependent RNase. The % identity to the corresponding domains of *S. cerevisiae* and *C. elegans* is indicated.

25 (C) *Amino acid sequence alignment of human Ire1p (H.s.), S. cerevisiae Ire1p (S.c.) and its putative homologous protein from C. elegans (C.e.).* Open boxes indicate the identical sequence. Shaded boxes indicate conserved residues. Dashes represent gaps between residues in order to obtain maximum matching. Numbers are the position of the last amino acid. ∇, potential signal peptide cleavage site; ●, invariant residues in protein kinase domain; *, indicates the invariant Lys599 residue in kinase subdomain II. The glutamine rich cluster (I) and the serine rich cluster (II) in the linker region are also identified.

Figure 2. *hIRE1* is ubiquitously expressed in human tissues.

Northern blot analysis of poly (A)⁺ RNA isolated from various human tissues (Clontech) by hybridization with ³²P-labeled-cDNA probes corresponding to the *hIRE1* luminal domain, the *hIRE1* cytoplasmic domain, or human β -actin cDNA. Exposure of the Ire1
5 autoradiogram was 24-fold longer than that of β -actin.

Figure 3. Over-expression of *hlre1p* in transiently transfected COS-1 monkey cells.

(A) *hlre1p* expression in transfected COS-1 cells. COS-1 cells were transiently transfected with or without expression plasmids encoding wild-type *hlre1p* (pED-*hIRE1*) or
10 its kinase defective mutant (pED-*hIRE1* K599A). Transfected cells were pulse-labeled with [³⁵S]-methionine and cysteine for 15 min. Cell extracts were prepared and equal amounts were immunoprecipitated with α -*hlre1p* antibodies and analyzed by SDS-PAGE and autoradiography.

(B) *Expression of eIF-2 α in co-transfected cells.* COS-1 cells were mock-
15 transfected (lane 1) or co-transfected with pED-eIF-2 α in the presence of pED (lane 2), pED-*hIRE1* (lane 3) or pED-*hIRE1* K599A (lane 4). The cells were pulse-labeled with [³⁵S]-methionine and cysteine for 15 min. Cell extracts were prepared and equal cpm of radiolabeled protein were analyzed directly by SDS-PAGE and autoradiography.

(C) *Functional hlre1p limits accumulation of hIRE1 mRNA.* Total RNA was
20 isolated from COS-1 cells transfected with pED, pED-*hIRE1* or pED-*hIRE1* K599A plasmid and treated in the presence (+) or absence (-) of cycloheximide. RNA samples (10 μ g) were resolved in a formaldehyde agarose gel, blotted onto nylon membrane and hybridized with ³²P- labeled *hIRE1* cDNA probe. Arrow indicates the *hIRE1* transcript.

(D) *hlre1p has intrinsic kinase activity.* Wild-type or K599A mutant *hlre1p* were
25 immunoprecipitated from transiently transfected COS-1 cells. Mock represents cells that did not receive plasmid DNA. The proteins were incubated in kinase buffer in the presence of [γ -³²P]-ATP at 30 °C for 40 min. The proteins were resolved by SDS-PAGE and transferred to a nitrocellulose membrane. The upper panel represents incorporation of ³²P phosphate into *hlre1p* determined by autoradiography. The lower panel represents
30 the *Ire1p* protein level determined by western blot analysis using α -*hlre1p* antibodies and alkaline phosphatase staining. The amount of K599A mutant *hlre1p* loaded onto the gel is 1/3 the amount of the immunoprecipitated proteins loaded for lanes 1 and 2. Therefore, the amount of steady state K599A mutant *hlre1p* is approximately 10-fold greater than the wild-type *hlre1p*.

Figure 4. hlre1p is a site-specific endoribonuclease.

- (A) *In vitro* cleavage of yeast *HAC1* mRNA by *hlre1p*. An *in vitro* transcribed [³²P]-labeled *HAC1* mRNA was incubated with *E. coli*-expressed GST or GST-*hlre1p* adsorbed to glutathione beads or with COS-1 cell-expressed *hlre1p* or *hlre1p* K599A protein adsorbed to protein A-sepharose beads. After the indicated period of time, the cleavage products were analyzed by electrophoresis on a 5% denaturing polyacrylamide gel. Schemes on the left depict the predicted cleavage products. Numbers on the right indicate predicted base pair size of RNA products expected based on yeast *HAC1* mRNA cleavage by yeast *Ire1p*. (Sidrauski, K. et al., *Cell* 90:1031-1039 (1997)).
- 10 (B) *hlre1p* cleaves yeast *HAC1* mRNA at residue G661. The *HAC1* RNA cleavage site was mapped using *in vitro* transcribed *HAC1* mRNA after incubation with GST, GST-*hlre1p*, *hlre1p* or *hlre1p* K599A as described in panel A. The products were reverse transcribed with Superscript II Reverse Transcriptase (Bethesda Research Labs) using oligonucleotide primer complementary to the intron of *HAC1* RNA. Sequencing ladders on the left represent *HAC1* DNA sequence determined with the same primer.
- 15 Arrow indicates the position of primer extended products.

Figure 5. *hlre1p* contains high-mannose core oligosaccharides.

- Transfected COS-1 cells that over-express *hlre1p* were pulse-labeled with [³⁵S]-methionine and cysteine for 15 min in the presence (lane 2) or absence (lane 1) of tunicamycin and cell extracts were prepared. In parallel, cells pulse-labeled 15 min in the absence of tunicamycin were incubated 3 hr in medium containing excess unlabeled methionine and cysteine before harvesting cell extracts. The [³⁵S]-labeled *hlre1p* was immunoprecipitated from cell extracts and analyzed by SDS-PAGE. Prior to SDS-PAGE, immunoprecipitated samples were incubated in the absence (lanes 1-3) or presence (lane
- 20
- 25 4) of endoglycosidase H.

Figure 6. Confocal laser scanning fluorescence microscopy of *hlre1p* expressed in COS-1 cells.

- The subcellular localization of *hlre1p* in transfected COS-1 cells was determined by immunofluorescence using mouse α -*hlre1p*. COS-1 cells transfected with wild-type (A) or K599A mutant (B) *IRE1* expression plasmids were double labeled with mouse α -*hlre1p* and rabbit α -GRP94. Transfected COS-1 cells transfected with wild-type *IRE1* expression plasmid were double labeled with mouse α -*hlre1p* and guinea pig α -RanGAP1 (C). Secondary antibodies used were either rhodamine-conjugated goat α -rabbit or rhodamine-conjugated goat α -guinea pig (red) in the presence of fluorescein-conjugated
- 30

goat α -mouse (green). The images were merged where colocalization is shown in yellow. Cells were viewed and digitally photographed with a Bio-Rad confocal fluorescence microscope. The bar represents 25 μ m.

Figure 7. hlre1p-dependent induction of UPR in mammalian cells.

5 The activation of the unfolded protein response was measured by co-transfection of COS-1 cells with a luciferase reporter plasmid under control of the rat BiP promoter, RSV- β -gal and either pED-*hIRE1* or pED-*hIRE1* K599A plasmid DNAs. At 60 hr post-transfection, the cells were treated with 10 μ g/ml tunicamycin for 6 hr. The luciferase activity was determined from triplicate independent transfection experiments and was
10 normalized to β -galactosidase activity to correct for transfection efficiency.

Figures 8A-8B. The nucleotide sequence of *hIRE1* of the present invention. The sequence information has been submitted to GenBank under accession no. AF059198 and is expressly incorporated by reference.

Figure 9. The amino acid sequence of hlre1p of the present invention. See also,
15 Tirasophon, W. et al., *Genes Dev.* 12:1812-1824 (1998), expressly incorporated by reference.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

A novel mammalian bifunctional protein kinase/endoribonuclease referred to herein as hlre1p, is provided. Also provided is a novel cDNA (*hIRE1*) encoding hlre1p.
20 The isolated cDNA is about 3.6 kbp long with an open reading frame extending from nucleotide 97 to 3030, encoding the novel mammalian protein, hlre1p.

The nucleic acid sequence of the cDNA encoding Ire1p and its deduced amino acid sequence are set forth in Figures 8A-8B and Figure 9, respectively. In a preferred embodiment, the isolated nucleic acid molecule of the invention comprises the nucleotide
25 sequence of Figures 8A and 8B, or homologues therefore. In another preferred embodiment, the isolated and purified polypeptide of the invention comprises the amino acid sequence of Figure 9, as well as biological equivalents.

Mammalian hlre1p is constitutively expressed in all tissues and is believed to be a functional homologue of the yeast Ire1p, for the following reasons. First, hlre1p and yeast
30 Ire1p are both type 1 transmembrane proteins in which the carboxy terminal domains are 34% identical at the amino acid level. Although the amino terminal halves of these two proteins have extensively diverged, the amino terminal half of hlre1p is 37% identical to a *C. elegans* putative gene product having a similar domain organization as hlre1p. The cytoplasmic domain of hlre1p contains all the conserved subdomains present in Ser/Thr

protein kinases and a carboxy terminal tail that displays greater homology to human RNase L than *S. cerevisiae* Ire1p. Second, hlre1p displays both intrinsic kinase activity measured by autophosphorylation capability and an endoribonuclease activity that specifically cleaved the 5' splice site of *S. cerevisiae* *HAC1* mRNA at the same nucleotide, 5 guanine 661, as the *S. cerevisiae* Ire1p. Third, over-expressed hlre1p is specifically localized to the ER, with particular concentration around the nuclear envelope. Fourth, over-expression of wild-type hlre1p constitutively activates a marker gene under control of the rat BiP promoter. Finally, over-expression of a catalytically inactive kinase mutant K599A completely prevents induction by tunicamycin, a treatment that promotes 10 accumulation of unfolded protein in the ER.

Without intending to be bound by theory, it is believed that hlre1p functions as the proximal sensor for the mammalian unfolded protein response (UPR). hlre1p induces the expression of protein chaperones of the endoplasmic reticulum, and in particular, expression of glucose-related proteins (GRPs), including, without limitation, BiP and 15 GRP94. Thus, by increasing the expression of *hIRE1* in a cell or providing increased quantities of hlre1p, expression of protein chaperones in said cell may be upregulated. Upregulation of protein chaperone expression can protect cells from death induced by calcium release from the ER, oxidative stress and anti-cancer treatments such as adriamycin and topoisomerase inhibitors. Conversely, by inhibiting the expression of 20 *hIRE1*, expression of the protein chaperones may also be down regulated. Inhibition of GRP induction increases sensitivity of cells to death in response to calcium release from the ER, oxidative stress, hypoxia and T cell mediated cytotoxicity.

Fragments of the protein of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the 25 protein may be in linear form or they may be cyclized using known methods, for example, as described in H.U. Saragovi, et al., *BioTechnology* 10:773-778 (1992) and in R.S. McDowell et al., *J. Amer. Chem. Soc.* 114:9245-9253 (1992). Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites. For example, fragments of the protein may 30 be fused through "linker" sequences to the Fc portion of an immunoglobulin. For a bivalent form of the protein, such a fusion could be to the Fc portion of an IgG molecule. Other immunoglobulin isotypes may also be used to generate such fusions. For example, a protein-IgM fusion would generate a decavalent form of the protein of the invention.

The present invention also provides a gene corresponding to the cDNA sequence

disclosed herein. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials.

In another aspect, DNA sequence information provided by the present invention allows for the preparation of relatively short DNA (or RNA) sequences or probes that are identical to or hybridize to the nucleotide sequence disclosed herein. Nucleic acid probes (also referred to as oligonucleotide probes) of an appropriate length are prepared based on a consideration of the nucleotide sequence of Figures 8A and 8B. The probes can be used in a variety of assays appreciated by those skilled in the art, for detecting the presence of complementary sequences in a given sample. The probes may be useful in research, prognostic and diagnostic applications. For example, the probes may be used to detect homologous nucleotide sequences, e.g., the human homolog. The design of the probe should preferably follow these parameters:

a) it should be designed to an area of the sequence which has the fewest ambiguous bases ("N's"), if any; and

b) it should be designed to have a T_m of approximately 80° C (assuming 2 degrees for each A or T and 4 degrees for each G or C). The oligonucleotide should preferably be labeled with γ -³²P ATP (specific activity 6000 Ci/mole) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Other labeling techniques can also be used. Unincorporated label should preferably be removed by gel filtration chromatography or other established methods. The amount of radioactivity incorporated into the probe should be quantitated by measurement in a scintillation counter. Preferably, specific activity of the resulting probe should be approximately 4e+6 dpm/mole.

A further preferred nucleic acid sequence employed for hybridization studies or assays includes probe molecules that are complementary to at least a 10 to 70 or so long nucleotide stretch of the polynucleotide sequence shown in Figures 8A and 8B. A size of at least 10 nucleotides in length helps to ensure that the fragment will be of sufficient length to form a duplex molecule that is both stable and selective. Molecules having complementary sequences over stretches greater than 10 bases in length are generally preferred in order to increase stability and selectivity of the hybrid, and thereby improve the quality and degree of specific hybrid molecules obtained. It will be appreciated that

nucleic acid molecules having gene-complementary stretches of 25 to 40 nucleotides, 55 to 70 nucleotides, or even longer where desired, may be preferred. Such fragments can be readily prepared by, for example, directly synthesizing the fragment by chemical means, by application of nucleic acid reproduction technology, such as the PCR
5 technology of U.S. Patent 4,683,202, or by excising selected DNA fragments from recombinant plasmids containing appropriate inserts and suitable restriction enzyme sites. In certain embodiments, it is also advantageous to use oligonucleotide primers. The sequence of such primers is designed using the polynucleotide of the present invention and is used with PCR technology.

10 The invention also encompasses allelic variants of the disclosed polynucleotide or protein; that is, naturally-occurring alternative forms of the isolated polynucleotide which also encode proteins which are identical, homologous or related to that encoded by the polynucleotide.

The isolated polynucleotide of the invention may be operably linked to an
15 expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al., *Nucleic Acids Res.* 19:4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, *Methods in Enzymology* 185:537-566 (1990). As defined herein "operably
20 linked" means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.

A number of types of cells may act as suitable host cells for expression of the
25 protein. Mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from *in vitro* culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.

30 Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kluyveromyces* strains, *Candida*, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include *Escherichia coli*, *Bacillus subtilis*, *Salmonella*

typhimurium, or any bacterial strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using
5 known chemical or enzymatic methods.

The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from,
10 e.g., Invitrogen, San Diego, Calif., U.S.A. (the MaxBac® kit) and such methods are well known in the art, as described in Summers and Smith, *Texas Agricultural Experiment Station Bulletin No. 1555* (1987). As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed."

The protein of the invention may be prepared by culturing transformed host cells
15 under culture conditions suitable to express the recombinant protein. The resulting expressed protein may be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column containing agents which will bind to the protein; one or more column steps over such
20 affinity resins as concanavalin A-agarose, heparin-toyopearl® or Cibacrom blue 3GA Sepharose®; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.

Alternatively, the protein of the invention may also be expressed in a form which
25 will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST), hexahistidine or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially available from New England BioLab (Beverly, Mass.), Pharmacia (Piscataway, N.J.) and InVitrogen, respectively. The protein can also be tagged with an
30 epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("Flag") is commercially available from Kodak (New Haven, Conn.).

Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or

all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein."

5 The protein of the invention may also be expressed as a product of transgenic animals, *e.g.*, as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.

The protein may also be produced by known conventional chemical synthesis.

10 Methods for constructing the protein of the present invention by synthetic means are known to those skilled in the art. The synthetically-constructed protein sequences, by virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. Thus, they may be employed as biologically active or
15 immunological substitutes for natural, purified protein in screening of therapeutic compounds and in immunological processes for the development of antibodies.

The protein provided herein also include protein characterized by amino acid sequences similar to those of purified protein but into which modifications are naturally provided or deliberately engineered. For example, modifications in the peptide of DNA
20 sequences can be made by those skilled in the art using known techniques. Modifications of interest in the protein sequence may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the conformation of the molecule. Techniques for such alteration,
25 substitution, replacement, insertion or deletion are well known to those skilled in the art (see, *e.g.*, U.S. Patent No. 4,518,584). Preferably, such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein.

Other fragments and derivatives of the sequence of the protein which would be expected to retain protein activity in whole or in part may thus be useful for screening or
30 other immunological methodologies may also be easily made by those skilled in the art given the disclosures herein. Such modifications are believed to be encompassed by the present invention.

In one embodiment, the present invention provides an antibody immunoreactive with the hlre1p polypeptide. Also contemplated by the present invention are antibodies

immunoreactive with homologues or biologically equivalent polynucleotides and polypeptides of the present invention. As used herein, the term "antibody" is used in its broadest sense to include polyclonal and monoclonal antibodies, as well as polypeptide fragments of antibodies that retain a specific binding activity for hIre1p. One skilled in the art will appreciate that anti-hIre1p antibody fragments such as Fab, F(ab)₂ and Fv fragments can retain specific binding activity for hIre1p and, thus, are included within the definition of an antibody. In addition, the term "antibody" as used herein includes naturally occurring antibodies as well as non-naturally occurring antibodies and fragments that retain binding activity. Methods of making antibodies are known in the art. See, e.g.,
5
10 Harlow and Lane, *Antibodies: A Laboratory Manual* (Cold Spring Harbor Press, 1988).

As used herein, the term "nucleic acid" is intended to mean natural and synthetic linear and sequential arrays of nucleotides and nucleosides, e.g. in cDNA, genomic DNA (gDNA), mRNA, and RNA, oligonucleotides, oligonucleosides and derivatives thereof. It will also be appreciated that such nucleic acids can be incorporated into other nucleic acid chains referred to as "vectors" by recombinant-DNA techniques such as cleavage and ligation procedures. The terms "fragment" and "segment" are as used herein with reference to nucleic acids (e.g., cDNA, genomic DNA, i.e., gDNA) are used interchangeably to mean a portion of the subject nucleic acid such as constructed artificially (e.g. through chemical synthesis) or by cleaving a natural product into a
15
20 multiplicity of pieces (e.g. with a nuclease or endonuclease to obtain restriction fragments). As used herein, "A" represents adenine; "T" represents thymine; "G" represents guanine; "C" represents cytosine; and "U" represents uracil.

As referred to herein, the term "encoding" is intended to mean that the subject nucleic acid may be transcribed and translated into the subject protein in a cell, e.g. when
25 the subject nucleic acid is linked to appropriate control sequences such as promoter and enhancer elements in a suitable vector (e.g. an expression vector) and the vector is introduced into a cell. The term "polypeptide" is used to mean three or more amino acids linked in a serial array.

As referred to herein, the term "capable of hybridizing under high stringency conditions" means annealing a strand of DNA complementary to the DNA of interest under highly stringent conditions. Likewise, "capable of hybridizing under low stringency conditions" refers to annealing a strand of DNA complementary to the DNA of interest under low stringency conditions. In the present invention, hybridizing under either high or low stringency conditions would involve hybridizing a nucleic acid sequence (e.g., the
30

complementary sequence to Figures 8A and 8B or portion thereof), with a second target nucleic acid sequence. "High stringency conditions" for the annealing process may involve, for example, high temperature and/or low salt content, which disfavor hydrogen bonding contacts among mismatched base pairs. "Low stringency conditions" would involve lower temperature, and/or lower salt concentration than that of high stringency conditions. Such conditions allow for two DNA strands to anneal if substantial, though not near complete complementarity exists between the two strands, as is the case among DNA strands that code for the same protein but differ in sequence due to the degeneracy of the genetic code. Appropriate stringency conditions which promote DNA hybridization, for example, 6X SSC at about 45 °C, followed by a wash of 2X SSC at 50 °C are known to those skilled in the art or can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, NY (1989), 6.31-6.3.6. For example, the salt concentration in the wash step can be selected from a low stringency of about 2X SSC at 50 °C to a high stringency of about 0.2X SSC at 50 °C. In addition, the temperature in the wash step can be increased from low stringency at room temperature, about 22 °C, to high stringency conditions, at about 75 °C. Other stringency parameters are described in Maniatis, T., et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring NY, (1982), at pp. 387-389; see also Sambrook J. et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Volume 2, Cold Spring Harbor Laboratory Press, Cold Spring, NY at pp. 8.46-8.47 (1989).

As used herein, the term "specifically binds" refers to a non-random binding reaction between two molecules, for example between an antibody molecule immunoreacting with an antigen.

The term "knockout" refers to partial or complete suppression of the expression of at least a portion of a protein encoded by an endogenous DNA sequence in a cell. The term "knockout construct" refers to a nucleic acid sequence that is designed to decrease or suppress expression of a protein encoded by endogenous DNA sequences in a cell. The nucleic acid sequence used as the knockout construct is typically comprised of 1) DNA from some portion of the gene (exon sequence, intron sequence, and/or promoter sequence) to be suppressed and 2) a marker sequence used to detect the presence of the knockout construct in the cell. Typically, the knockout construct is inserted into an embryonic stem cell (ES cell) and is integrated into the ES cell genomic DNA, usually by the process of homologous recombination. This ES cell is then injected into, and integrates with, the developing embryo.

The phrases "disruption of the gene" and "gene disruption" refer to insertion of a nucleic acid sequence into one region of the native DNA sequence (usually one or more exons) and/or the promoter region of a gene so as to decrease or prevent expression of that gene in the cell as compared to the wild-type or naturally occurring sequence of the gene. By way of example, a nucleic acid construct can be prepared containing a DNA sequence encoding an antibiotic resistance gene which is inserted into the DNA sequence that is complementary to the DNA sequence (promoter and/or coding region) to be disrupted. When this nucleic acid construct is then transfected into a cell, the construct will integrate into the genomic DNA. Thus, many progeny of the cell will no longer express the gene at least in some cells, or will express it at a decreased level, as the DNA is now disrupted by the antibiotic resistance gene.

The term "marker sequence" refers to a nucleic acid sequence that is 1) used as part of a nucleic acid construct (*i.e.*, the "knockout construct") to disrupt the expression of the gene(s) of interest (*e.g.*, *hIRE1*), and 2) used as a means to identify those cells that have incorporated the knockout construct into the genome. The marker sequence may be any sequence that serves these purposes, although typically it will be a sequence encoding a protein that confers a detectable trait on the cell, such as an antibiotic resistance gene or an assayable enzyme not typically found in the cell. Where the marker sequence encodes a protein, the marker sequence will also typically contain a promoter that regulates its expression.

The term "progeny" refers to any and all future generations derived and descending from a particular mammal, *i.e.*, a mammal containing a knockout construct inserted into its genomic DNA. Thus, progeny of any successive generation are included herein such that the progeny, the F1, F2, F3, generations and so on indefinitely are included in this definition.

The foregoing and other aspects of the invention may be better understood in connection with the following example, which is presented for purposes of illustration and not by way of limitation.

SPECIFIC EXAMPLE

I. RESULTS

Isolation of complementary DNA encoding human *Ire1p*. To screen for a human homologue of *S. cerevisiae IRE1*, degenerate oligonucleotide primers were designed from the amino acid sequence (ISDFGLCK) in the kinase subdomain VII of *S. cerevisiae IRE1* that was also conserved in a putative *C. elegans IRE1* identified in the

genbank, but was not present in other protein Ser/Thr protein kinases. The oligonucleotide was used in combination with a λ gt 10 specific primer to amplify DNA fragments from a human fetal liver cDNA library. RH3 was isolated as a candidate clone containing a 270 bp PCR product, that encoded for a portion of the catalytic domain of a novel human Ser/Thr protein kinase. The clone was used as a probe to screen for overlapping clones from a human fetal liver cDNA library (Fig. 1A). A 3.5 kb cDNA was assembled from overlapping clones that has a single open reading frame encoding 977 amino acid residues with a predicted molecular mass of 110 kDa (Fig. 1C). One clone had a 106 bp putative 5' untranslated region that did not contain either an ATG codon or an in frame termination codon upstream of the ATG codon having a favorable sequence context (CGCCATGCC) to serve as an initiation codon. Kozak, M., *Nucl. Acids Res.* 15:8125-8248 (1987). In addition, immediately following the putative initiation codon was a sequence of residues that are predicted to serve as a signal peptide, having positively charged residues at the extreme N-terminus followed by a core of hydrophobic residues and then turn inducing residues (Pro and Gly). Nielsen, H. et al., *Protein Eng.* 10:1-6 (1997). We predict that signal cleavage occurs after Gly18. Finally, one clone (13-1) was identified that contained a 3' untranslated region of 598 bp that contained multiple translation termination codons in all reading frames, but did not contain a conserved polyadenylation signal, suggesting additional sequence exists within the 3' untranslated region of the mRNA. On the basis of these observations, it is believed the intact coding region for this putative kinase is cloned.

A hydropathy plot of the deduced amino acid sequence revealed that it contained two stretches of hydrophobic residues: a leucine rich motif close to the amino terminus that could function as a signal sequence and a stretch of 21 consecutive hydrophobic residues lying approximately in the middle of the molecule that could provide a transmembrane domain. This suggested that the putative protein is a type 1 transmembrane protein with the kinase domain in the carboxy terminus and with a single potential N-linked glycosylation site (Asn-Ala-Thr) in the luminal domain at residue 176 (Fig. 1B).

Searches of the protein sequence database suggested that the carboxy terminal half of the protein could be divided into 3 domains: a linker region, the putative Ser/Thr protein kinase domain, and an RNase L-like domain homologous to 2'-5' oligo A-dependent ribonuclease (Fig. 1B). The linker region is unique to the human protein and contains two subdomains rich in glutamine and serine residues, respectively. In contrast,

the kinase domain displays high homology with both that of *S. cerevisiae* Ire1p and its putative counterpart from *C. elegans*, having conserved all 12 invariant residues that are present within the protein kinase superfamily (Fig. 1C). Hanks, S.K. et al., *FASEB J.* 9:576-596 (1995). The similarity among these three proteins also extends to the very
5 carboxy terminal RNase L domain (Fig. 1C). Zhou A. et al., *Cell* 72:753-765 (1993). The cytoplasmic domain of hlre1p, as well as its putative counterpart from *C. elegans* do differ from yeast Ire1p in that they do not contain a potential nuclear localization signal and also lack an insertion of 30 hydrophilic amino acids between conserved kinase subdomains VIII and IX. Mori, K. et al., *Cell* 74:743-756 (1993). In contrast, the amino terminal half of
10 the protein was less conserved, with the *C. elegans* protein and displayed no significant similarity with *S. cerevisiae* Ire1p. Based on the homologies within the cytoplasmic domain, this putative human protein is referred to as human Ire1p (hlre1p).

hIRE1 is constitutively expressed in all tissues The expression of endogenous *hIRE1* was studied by Northern blot hybridization to ³²P-labeled cDNA
15 probes corresponding to either the luminal domain or the cytoplasmic domain of hlre1p. The hybridization patterns with these 2 probes were identical (Fig. 2). *hIRE1* was ubiquitously expressed at low levels as detected by a single species of mRNA migrating at approximately 8 kb in all tissues examined. Based on the size of endogenous *hIRE1* mRNA together with its predicted translation product, it is suggested that *hIRE1* mRNA
20 contains a long, approximately 4 kb, 3' untranslated region. Interestingly, the *hIRE1* mRNA was most abundant in pancreatic tissue, suggesting that hlre1p might play a significant role in this particular organ.

hlre1p displays kinase activity that is required to down-regulate its synthesis. To examine the biochemical properties of hlre1p, antibodies were raised in
25 mice immunized with a glutathione-S-transferase (GST)-hlre1p fusion protein. Although this polyclonal antibody reacted with the antigen against which it was raised, the antibody did not detect endogenous Ire1p upon immunoprecipitation from several human cell lines, suggesting that the level of endogenous hlre1p is extremely low (data not shown). In order to obtain sufficient amount of protein for characterization, hlre1p was over-
30 expressed in COS-1 monkey cells by transient DNA transfection of the cDNA cloned in the expression vector pED. Kaufman, R.J. et al., *Nucl. Acids Res.* 19:4485-4490 (1991). In addition, an expression vector encoding a kinase defective *hIRE1* mutant was constructed in which the conserved lysine at residue 599 in the putative ATP binding site was substituted by alanine (pED-*hIRE1* K599A). Hanks, S.K. et al., *Methods Enzymol.*

200:38-62 (1991). The expression of these proteins was monitored by immunoprecipitation of cell extracts from [³⁵S]-methionine and cysteine pulse-labeled cells using α -hlre1p antibody. As expected, both wild-type and K599A mutant hlre1p were expressed as 110 kDa proteins (Fig. 3A). This protein product was not detected from mock-transfected cells or from pED vector-transfected cells (Fig. 3A and data not shown). Interestingly, the level of mutant K599A hlre1p synthesis in transfected COS-1 cells was approximately 16 times higher than that of the wild-type hlre1p. The difference between wild-type and mutant hlre1p expression was not attributable to differences in transfection efficiency (determined by immunofluorescence) and different independent isolates of both plasmid DNAs yielded similar results. The increased synthesis of mutant hlre1p could account for the increased steady state level (approximately 10-fold from Fig. 3D), suggesting there is no significant difference in the rate of degradation.

The difference in the expression level between wild-type and the K599A mutant hlre1p protein in transfected COS-1 cells (Fig. 3A) lead to a speculation that hlre1p might autoregulate its expression. Alternatively, over-expression of wild-type hlre1p may inhibit general expression in the subpopulation of transiently transfected cells due to general toxicity. To address this possibility, COS-1 cells were co-transfected with another marker gene encoding the eukaryotic translation initiation factor eIF-2 α subunit (pED-eIF-2 α) with either pED-*hIRE1* or pED-*hIRE1* K599A. The transfected cells were metabolically pulse-labeled with [³⁵S]-methionine and cysteine and protein synthesis was analyzed by SDS-PAGE of total cell extract samples. The presence of either hlre1p or its mutant (K599A) had no effect on the synthesis of eIF-2 α , suggesting that wild-type hlre1p over-expression is not toxic and does not inhibit global gene expression in the transfected cells (Fig. 3B; compare lane 3 to lanes 2 and 4).

To further investigate the mechanism for the reduced expression of wild-type hlre1p, the level of plasmid derived *hIRE1* mRNA from COS-1 transfected cells was analyzed. Total RNA was prepared from COS-1 cells transfected with pED, pED-*hIRE1* or pED-*hIRE1* K599A and treated in the presence or absence of cyclohexamide for 12 hr before harvesting RNA. Northern blot hybridization demonstrated the level of *hIRE1* K599A mRNA was 10 times higher than the wild-type *hIRE1* mRNA derived from the transfected DNA (Fig. 3C). Inhibition of protein synthesis by cyclohexamide had no effect on the steady state level of these mRNAs, suggesting that ongoing protein synthesis is not required to down-regulate *hIRE1* mRNA. Taken together, it was concluded that functional hlre1p downregulates its own expression at the level of mRNA production and/or stability.

The deduced amino acid sequence of hlre1p suggested the presence of an intact catalytic Ser/Thr protein kinase domain. To demonstrate functional activity of the kinase, the capability for autophosphorylation was measured, since this activity correlates with functional activity of yeast Ire1p. Welihinda, A.A. et al., *J. Biol. Chem.* 271:18181-18187 (1996). The wild-type and mutant K599A hlre1p were immunoprecipitated from transfected COS-1 cells and incubated in kinase buffer with [γ - 32 P]-ATP. The proteins were then resolved by SDS-PAGE and transferred onto a nitrocellulose membrane prior to autoradiography and probing with α -hlre1p antibody. The wild-type hlre1p was efficiently autophosphorylated (Fig. 3D). The phosphorylation resulted in a slightly slower mobility as determined by western blotting. Substitution of the conserved lysine residue in the putative ATP binding pocket with alanine significantly reduced the phosphorylation detected, especially when corrected for the greater amount of protein immunoprecipitated (Fig. 3D; compare lanes 2 and 3). The low level of phosphorylation of this mutant Ire1p may result from either the presence of endogenous COS-1 cell-derived Ire1p or another kinase(s) in the immunoprecipitation reaction. Taken together, it was concluded that hlre1p displays an intrinsic protein kinase activity.

hlre1p is a bifunctional enzyme having an endoribonuclease activity specific to yeast HAC1 mRNA. Sidrauski and Walter (*Cell* 90:1031-1039 (1997)) recently demonstrated that the cytoplasmic domain of yeast Ire1p exhibits a site-specific endoribonuclease activity capable of cleaving *HAC1* mRNA at both the 5' and 3' splice site junctions *in vitro*. The proposed catalytic domain of RNase L indeed displays greater sequence similarity to hlre1p than to the yeast Ire1p. This led to the hypothesis that hlre1p might exhibit a similar endoribonuclease activity and may be able to catalyze the same specific RNA cleavage as observed for yeast Ire1p. Since the identity of the mammalian *HAC1* homologue is unknown, it was determined whether yeast *HAC1* mRNA could serve as a substrate to test for an endoribonuclease activity of hlre1p. A 550 nucleotide substrate derived from *S. cerevisiae HAC1* mRNA that contained both the 5' and 3' splice site junctions was synthesized *in vitro*. Incubation of this substrate in the presence of a GST-yeast Ire1p fusion protein simultaneously cleaved the *HAC1* mRNA substrate at the 5' and 3' splice site junctions, as previously shown by Sidrauski and Walter (1997). The cleavage generated 3 species of RNA products (corresponding to a 224 nt 5' exon, a 252 nt intron and a 74 nt 3' exon) and 2 intermediates (corresponding to a 476 nt 5'exon/intron and a 326 nt intron/3'exon) (Fig. 4A; lanes 3,4). The cleavage was not observed in the absence of GST-Ire1p, or with control GST protein alone (Fig. 4A;

lanes 1,2). Surprisingly, hlre1p isolated by immunoprecipitation from transfected COS-1 cells that over-express hlre1p was able to catalyze cleavage, however, only two species of RNA products were observed in this reaction (Fig. 4A; lanes 8,9). The two products appeared to be the same size as those derived from GST-yeast Ire1p mediated cleavage at only the 5' splice site junction (representing the 224 nt 5' exon and the 326 nt intron/3'exon). Prolonged incubation of the substrate with hlre1p did not generate the intron or the 3' exon fragments (data not shown). In contrast, no cleavage was observed when the mutant K599A hlre1p was substituted for hlre1p (Fig. 4A; lanes 6,7). Taken together, it was concluded that hlre1p exhibits endoribonuclease activity and its intrinsic kinase activity is required to elicit the endoribonuclease activity.

To precisely map the hlre1p cleavage site in *HAC1* mRNA, primer extension analysis was performed. An antisense oligonucleotide complementary to the *HAC1* intron was used to reverse transcribe *HAC1* mRNA cleaved by either *E. coli* expressed GST-yeast Ire1p or hlre1p expressed and immunoprecipitated from transfected COS-1 cells. The same primer was also used to determine the nucleotide sequence of the *HAC1* gene (Fig. 4B). The length of primer extended products derived from *HAC1* mRNA cleaved with GST-ylre1p and hlre1p were identical, indicating that both GST-yeast Ire1p and hlre1p cleave *HAC1* mRNA at the same position at the predicted 5'exon/intron junction (Fig. 4B; compare lanes 2 and 4). Comparison of these two extended products to the *HAC1* DNA sequence ladder indicated that they both were terminated after the guanine at residue 661. In contrast, this primer extended product was not observed in the reverse transcription reactions of *HAC1* mRNA incubated with control GST from *E. coli* or with control immunoprecipitated protein from either pED-*hIRE1* K599A- or mock- transfected cells.

hlre1p is an ER membrane protein preferentially localized to the nuclear envelope. ER resident glycoproteins that do not transit to the Golgi complex have high mannose-containing oligosaccharides that are sensitive to digestion by endoglycosidase H. The presence of a single potential N-linked glycosylation site in the N-terminal domain of hlre1p was used to determine the subcellular localization of hlre1p. hlre1p immunoprecipitated from extracts prepared from metabolically labeled transfected cells treated with tunicamycin, a drug that inhibits addition of N-linked core oligosaccharides, displayed a slightly reduced molecular mass compared to Ire1p isolated from untreated cells, suggesting the absence of the single N-linked core oligosaccharide (Fig. 5; compare lanes 1 and 2). Treatment of immunoprecipitated hlre1p with endoglycosidase H

decreased the molecular mass of the labeled hlre1p to that comparable to unglycosylated hlre1p isolated from tunicamycin treated cells (Fig. 5; compare lanes 2 and 4). In addition, deletion of the carboxy-terminal 462 amino acid residues (the putative cytosolic domain) generated a protein that contained an N-linked oligosaccharide (data not shown).

- 5 These results support localization of hlre1p to the ER which is consistent with the predicted topology of hlre1p having its amino termini in the ER lumen, similar to yeast Ire1p. Mori, K. et al., *Cell* 74:743-756 (1993).

Confocal laser scanning immunofluorescence microscopy was used to identify the hlre1p subcellular localization. COS-1 cells were transiently transfected with the wild-type
10 *hlRE1* expression plasmid and cells were double labeled with mouse antibody specific to hlre1p and rabbit antibody specific to GRP94, a resident protein of the ER. The immune complexes were visualized by secondary antibody conjugated with fluorescein isothiocyanate (FITC) or rhodamine, respectively (Fig. 6A). It was not possible to detect staining of hlre1p in non-transfected cells, possibly due to its low level of expression. In
15 contrast, wild-type hlre1p was detected in transfected cells as perinuclear fluorescence and appeared similar to the fluorescence pattern observed for endogenous GRP94. Although the fluorescence patterns of the two proteins were similar, analysis of the merged images suggested that hlre1p was preferentially localized close to the nuclear membrane. Significantly greater staining was observed in cells transfected with the *hlRE1*
20 mutant K599A expression plasmid, consistent with its greater level of expression (Fig. 6B).

The mutant hlre1p protein was also preferentially localized to the perinuclear region indicating that the kinase activity is not required for this localization. In order to determine if hlre1p was localized to the nuclear envelope, the fluorescence pattern of wild-type hlre1p was compared to that of endogenous RanGAP1 protein, a component of the
25 nuclear pore complex. Mahajan, R. et al., *Cell* 88:97-107 (1997). Unlike hlre1p which was localized to the ER membrane throughout the cytoplasm, RanGAP1 protein exhibited a specific nuclear rim fluorescence staining pattern. Interestingly, when the two fluorescence images were merged, a sub-population of hlre1p indeed co-localized with the nuclear pore complex protein RanGAP1 (Fig. 6C).

- 30 ***Over-expression of kinase defective K599A hlre1p blocks the unfolded protein response in mammalian cells.*** The previous data demonstrate that hlre1p displays several features similar to those of *S. cerevisiae* Ire1p. To directly test whether hlre1p plays an essential role in the UPR in mammalian cells, a mammalian reporter plasmid was constructed by inserting a 0.5 kb fragment of the rat BiP promoter, including

the *cis*-acting element capable of mediating the UPR (Chang, S.C. et al., *Proc. Natl. Acad. Sci. USA*. 84:680-684 (1987)), upstream from a luciferase coding region. The UPR reporter plasmid was co-transfected with either wild-type or the mutant K599A hIre1p expression vectors into COS-1 cells. The luciferase activity reflects the activation of the UPR in these cells. Luciferase activity was detected in extracts from cells transfected with the reporter plasmid alone and this activity was further increased 3-fold by treatment of the cells with tunicamycin (Fig. 7). Co-transfection of the reporter plasmid with pEDhIRE1 K599A prevented induction of the UPR upon tunicamycin (Tm) treatment. The inability to elicit the response suggests that the mutant hIre1p can act as a *trans*-dominant negative kinase to downregulate endogenous Ire1p. In contrast, over-expression of wild-type hIre1p caused constitutive induction of the UPR that was not further increased by treatment with tunicamycin. These results are consistent with those previously reported for expression of yeast Ire1p in *S. cerevisiae* (Mori, K. et al., *Cell* 74:743-756 (1993); Shamu, C.E. et al., *EMBO J.* 15:3028-3039 (1996)) and support the conclusion that hIre1p is a proximal sensor of the UPR pathway in mammalian cells.

II. MATERIALS AND METHODS

Cloning of human IRE1 cDNA. A degenerate antisense oligonucleotide [5' (TC)TT (AG)CT IT(AG) ICC (AG)AA (AG)TC IG(AT) IAT 3'] was designed from the conserved amino acid sequence in kinase subdomain VII (ISDFGLCK) between *S. cerevisiae* IRE1/ERN1 and its putative homologue from *C. elegans*. Inosine was incorporated into positions to minimize degeneracy and improve stability upon hybridization (Sambrook, J., Fritsch, E.F. and Maniatis, T. 1989. Molecular cloning: A laboratory manual (Cold Spring Harbor, New York: Cold Spring Harbor Laboratory press)). This primer and a λ gt 10 specific primer were used to amplify sequences from a human fetal liver cDNA library (Clontech). Total PCR products were ligated into the TA cloning vector (Invitrogen) and transformed into *E. coli* DH5 α . A candidate clone, RH3, that showed highest homology to the yeast IRE1 and its counterpart gene in *C. elegans* was subsequently used to screen the λ gt 10 human fetal liver cDNA library by standard procedures (Sambrook, J., Fritsch, E.F. and Maniatis, T. 1989. Molecular cloning: A laboratory manual (Cold Spring Harbor, New York: Cold Spring Harbor Laboratory press)). The 5' end of the hIRE1 (F14) was obtained by 5' rapid amplification of cDNA ends (RACE) PCR (Bethesda Research Labs) using template RNA isolated from the human hepatoma cell line HepG2. Each cDNA fragment was subcloned into pBluescript II SK(-) plasmid (Stratagene) at the *EcoR* I site. All cDNA fragments were sequenced from

both directions using the dideoxynucleotide sequencing method (Sequenase, Amersham).

pBluescript -13-1 is a recombinant plasmid containing the largest open reading frame of hlre1p but lacking the 5' end fragment. To assemble the full length *hIRE1* cDNA, the 0.3 kb PCR product including the initiator methionine was amplified from pBluescript-F14 using two primers: 1058G (5' GCT CTA GAA CCA TGC CGG CCC GGC GGC T 3') and 865G (5' AGG CTG CCA TCA TTA GGA TCT 3') and Vent DNA polymerase (New England Biolabs). The 0.3 kb PCR product was introduced into clone 17-1 by overlap-extension PCR using two primers: 1058G and 9241B (5' CAT TGA TGT GCA TCA CCT TCC TC 3') to yield a 0.7 kb PCR product. The 0.7 kb fragment was digested with *Xba* I, located upstream to the first ATG introduced by PCR, and *Bam*H I. The fragment was ligated to pBluescript-17-1 at the same restriction endonuclease sites to yield pBluescript-17-1/5'. The 0.9 kb *Xba* I/*Sac* II fragment from pBluescript-17-1/5' was ligated to pBluescript -13-1 at the same sites to yield pBluescript *-hIRE1*. The 3.5 kb *Xba* I/*Eco*R I *hIRE1* cDNA was subcloned into the *Xba*I site of the mammalian expression vector, pED (pED Δ C) (Kaufman, R.J. et al., *Nucl. Acids Res.* 19:4485-4490 (1991)) to yield pED-*hIRE1*.

Site directed mutagenesis. The conserved lysine residue at position 599 in kinase subdomain II was mutated by a PCR-based method using Vent DNA polymerase (New England Biolabs). The *Mst*I and *Pvu*I fragment from pED-*hIRE1* was replaced with the homologous fragment containing mutated sequence (AAG \rightarrow GCG) to yield pED-*hIRE1* K599A. The mutation was confirmed by DNA sequencing.

Antibody production. The 1.6 kb cDNA encoding the entire cytoplasmic domain of hlre1p (amino acid residues 460 to 977) was generated by PCR amplification using primer 168G (5' CGG AAT TCA TCA CCT ATC CCC TGA GCA TG 3'), 169G (5' CGG AAT TCT CAG AGG GCG TCT GGA GTC A 3') and Vent DNA polymerase (New England Biolabs). In order to make GST-hlre1p fusion protein, the PCR product was inserted in frame into pGEX-1 λ T (Pharmacia) at the *Eco*R I site and then transformed into *Escherichia coli* DH5 α . The fusion protein was produced and purified as described by Frangioni and Neel (*Cell* 57:1069-1072 (1993)) except that the induction was performed at 30°C. The purified GST-cytoplasmic hlre1p fusion protein was repeatedly injected into mice as described by Harlow and Lane (1988). Sera collected from tail bleed was used for determining the titer by Western blot analysis. When optimal titer was obtained, the mice were injected with the sarcoma cell line S180 to induce ascites fluid that was directly used. Harlow, E. and Lane, D. 1988. Antibodies: A laboratory manual (Cold Spring

Harbor, New York: Cold Spring Harbor Laboratory press).

Transient DNA transfection and analysis. COS-1 monkey cells were transfected as previously described. Kaufman, R.J., *Methods Mol. Biol.* 62:287-300 (1997). Briefly, cells were plated the day before transfection. Cells were transfected with 2 µg/ml of pED-hIRE1 or pED-hIRE1 K599A plasmid DNA by the diethylaminoethyl-dextran method for 6 hr. The cells were fed with fresh media at 36 hr post-transfection. Total cell extract was prepared from the transfected cells at 60 hr post-transfection by using Nonidet P-40 lysis buffer (1% NP-40, 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% SDS) supplemented with 1 mM phenylmethylsulfonylfluoride, 40 µg/ml aprotinin, and 20 µg/ml leupeptin. For metabolic labeling (unless otherwise specified), the transfected cells were labeled with [³⁵S]-methionine and cysteine (1000 Ci/mole, Amersham Corp.) for 15 min before harvesting cells. For immunoprecipitation, cell extract was preabsorbed with protein A sepharose. The precleared lysate was subsequently incubated with α-hlre1p for 14 hr at 4°C and then incubated with rabbit α-mouse IgG antibodies for 1 hr. The immune complexes were adsorbed with protein A sepharose and successively washed with phosphate buffered saline (PBS) containing Triton X-100 at 1%, 0.1% and 0.05%. Samples were analyzed by SDS-PAGE under reducing conditions and autoradiography. Band intensities were quantified using the NIH Image 1.55b program.

Northern Blot analysis. Poly (A)⁺ RNA isolated from various human tissues (Clontech) was hybridized with ³²P-labeled- 1.5 kb *Nsi* I/ *Pvu* I fragment of *hIRE1* cDNA corresponding to the luminal domain of hlre1p, the 0.9 kb *EcoR* I insert fragment of pBluescript-9-1 corresponding to the cytoplasmic domain of hlre1p, or 2 kb human β-actin cDNA (Clontech). The hybridization was performed in ExpressHyb Hybridization buffer according to the manufacturer's instructions (Clontech).

Total RNA from transfected COS-1 cells were prepared by using TRIzol reagent (Bethesda Research Labs). RNA (10 µg) was resolved in 1% formaldehyde agarose gel and blotted onto Hybond nylon membrane (Amersham). Blot were hybridized with ³²P labeled 0.9 kb *EcoR* I fragment of hIRE-1 pBluescript-9-1 as described. Sambrook, J., Fritsch, E.F. and Maniatis, T. 1989. Molecular cloning: A laboratory manual (Cold Spring Harbor, New York: Cold Spring Harbor Laboratory press).

In vitro phosphorylation and western blotting. Immunoprecipitated protein from transfected COS-1 cells was incubated in kinase buffer {50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM MnCl₂, 1 mM MgCl₂, 1 mM Na₂MoO₄, 2 mM NaF, 1 mM dithiothreitol and 10 µCi [γ-³²P]-ATP (6000 Ci/mole, Amersham Corp.)} at 30°C for 40 min. The protein

samples were resolved by electrophoresis on an SDS-10% polyacrylamide gel and then transferred onto a nitrocellulose membrane. The membrane was probed with mouse α -hlre1p antibody followed with goat α -mouse antibody conjugated with alkaline phosphatase. The phosphorylation was quantified by autoradiography.

5 **Confocal immunofluorescence microscopy.** Immunofluorescence staining was followed as described by Paterson et al. *Meth. Enzymol.* 256:162-173 (1995). Briefly, COS-1 cells were plated onto coverslips and transfected with pED-hIRE1 plasmid as described above. At 60 hr post-transfection, the transfected cells were stained with mouse α -GST-hlre1p and either rabbit α -GRP94 or guinea pig α -RanGAP1. The cells
10 were then incubated with secondary antibodies (goat α -mouse IgG conjugated with fluorescein isothiocyanate and goat α -rabbit or goat α -guinea pig conjugated with rhodamine) (Boehringer Mannheim), washed, and mounted onto slides with Prolong mounting (Molecular Probes). The fluorescence images were examined using a confocal laser scanning fluorescence microscope (Bio-Rad MRC 600).

15 **In vitro cleavage of HAC1 mRNA.** The procedure followed was previously described by Sidrauski and Walter, *Cell* 90:1031-1039 (1997). Briefly, a 550 bp fragment of HAC1 DNA fragment flanking the intron region (Mori, K. et al., *Genes to Cells*. 1:803-817 (1996)) was PCR amplified from *S. cerevisiae* genomic DNA and subcloned into pBluescript II SK (-) plasmid (Stratagene) at *Pst* I and *Xho* I sites (pBluescript-HAC1).
20 HAC1 mRNA was transcribed *in vitro* from *Xho* I digested pBluescript-HAC1 using T7 RNA polymerase (Boehringer Mannheim) in the presence of α ³²P-UTP (3000 Ci/mmmole, Amersham Corp.). The RNA was resolved by electrophoresis in a 5% denaturing polyacrylamide gel and the ³²P-labeled HAC1 mRNA was purified as described (Sidrauski, K. et al., *Cell* 90: 1031-1039 (1997)) and dissolved in endonuclease buffer (20 mM
25 Hepes, 1 mM DTT, 10 mM MgOAc, 50 mM KOAc, 2 mM ATP). Purified RNA (3 x10⁶ cpm) was added to the immunoprecipitated hlre1p, hlre1p K599A, or 0.5 μ g GST-cytoplasmic Ire1p (Welihinda, A.A. et al., *J. Biol. Chem.* 271:18181-18187 (1995)) in final volume 100 μ l reaction. After incubating at 30°C for the indicated time, the reaction was terminated by extraction with phenol/ chloroform, precipitated with ethanol, and analyzed
30 by electrophoresis on are 5% denaturing polyacrylamide gel. Gels were dried prior to autoradiography.

Primer extension. The procedure was followed as described by Sambrook et al., *Molecular cloning: A laboratory manual* (Cold Spring Harbor, New York: Cold Spring Harbor Laboratory press) (1989).

Luciferase assay. To construct the pBiP-luciferase reporter plasmid, the promoter region of rat BiP gene including the putative unfolded protein response element (nt -457 to +33; Chang, S.C. et al., *Proc. Natl. Acad. Sci. USA* 84:680-684 (1987)) was amplified by PCR and subcloned into the *Kpn* I and *Hind* III sites of pGL3-basic vector (Promega). Each 10 cm plate of COS-1 cells was co-transfected with pBiP-luciferase reporter plasmid (2 μ g), RSV β -gal (2 μ g) and pED-*hIRE1* or pED-*hIRE1* -K599A (4 μ g each) by the calcium phosphate procedure. Chen, C.A. et al., *BioTechniques* 6:632-638 (1988). At 60 hr post-transfection, cells were treated with or without 10 μ g/ml tunicamycin for 6 hr. Preparation of the cell lysate, β -galactosidase assays and luciferase assays were performed according to manufacturer's instructions (Promega). The luciferase activity was normalized to β -galactosidase activity.

III. DISCUSSION

hIre1p has an intrinsic autophosphorylation and endoribonuclease activity. Previous studies on the yeast *Ire1p* demonstrated that the endoribonuclease activity required an adenine nucleotide as a cofactor. Since, a nonhydrolyzable analogue AMP-PNP and ADP stimulated the activity as well as ATP, it was thought that the endoribonuclease activity of yeast *Ire1p* did not require the kinase activity. As demonstrated in the present invention, the mutant K599A *hIre1p* had defective kinase activity as well as endoribonuclease activity, suggesting that autophosphorylation is required to elicit the endoribonuclease activity, possibly by phosphorylation of residues within its endoribonuclease domain. The studies presented herein suggest that the *hIre1p* endoribonuclease activity requires autophosphorylation as well as an adenine nucleotide. However, the K599A mutant *Ire1p* may be defective in endoribonuclease activity as a consequence of altered nucleotide binding, and not necessarily due to a requirement for autophosphorylation. *hIre1p* was able to cleave the yeast *HAC1* mRNA substrate at the identical 5' splice site as yeast *Ire1p*. However, primer extension analysis identified the 5' cleavage site was after guanine 661, in contrast to previous primer extension analysis that identified cytosine 660 as the 5' cleavage site (Sidrauski and Walter 1997), but consistent with the recent characterization of *in vivo* spliced products derived from mutated templates (Kawahara et al. 1998). Whereas the primer extension analysis of the present invention was compared to a DNA sequencing ladder derived from a reaction using the same primer for extension, Sidrauski and Walter (*Cell* 90:1031-1039 (1997)) used a different primer and this may explain the discrepancy. Although *hIre1p* efficiently cleaved the 5' splice site of yeast *HAC1* mRNA, there was no detectable cleavage at the 3' splice site.

This is consistent with observations that hIre1p was not able to complement *S. cerevisiae* deleted of *IRE1*. The complete cleavage of *HAC1* mRNA at both splice sites is required for the UPR function in yeast. Sidrauski, K. et al., *Cell* 90:1031-1039 (1997); Kawahara, T. et al., *J. Biol. Chem.* 273:1802-1807 (1998). The inability for hIre1p to cleave the yeast
5 *HAC1* mRNA 3' splice site was surprising since Kawahara et al. (*J. Biol. Chem.* 273:1802-1807 (1998)) recently demonstrated that the sequence requirements for the 5' and 3' splice site cleavages within *HAC1* mRNA by yeast Ire1p are remarkably similar. However, there were a couple nucleotide differences in cleavage specificity identified between the 5' and 3' splice sites, particularly the +1 position and the +5 position with respect to the site
10 of cleavage. Therefore, the hIre1p cleavage specificity for the 3' splice site may have diverged from the yeast Ire1p. Alternatively, there may be another homologue of hIre1p that displays a different cleavage specificity restricted to the 3' splice site of a human *HAC1* mRNA homologue, and the two nucleolytic events required to release the intron may require a heterodimer, of which each subunit has unique specificity to catalyze
15 cleavage at either the 5' or 3' splice site. This latter possibility is observed in the cleavage specificity of yeast tRNA endonuclease, where two subunits are required, each having its own active site that recognizes either the 5' or 3' splice site of precursor tRNA molecules. Trotta, C.R. et al., *Cell* 89:849-858 (1997).

Expression of wild-type hIre1p was approximately 16-fold reduced compared to
20 K599A catalytically inactive mutant hIre1p. The reduced expression of the wild-type kinase was not due to a general toxicity or transcriptional inhibition specific to the promoter used in the expression vector since expression of a co-transfected cDNA, eIF-2 α , contained within the same expression vector was not reduced in the presence of the wild-type hIre1p kinase expression vector. Analysis of mRNA demonstrated that the wild-type
25 kinase also had a corresponding decrease in the steady state level of mRNA compared to the mRNA encoding the K599A mutant Ire1p. Since the K599A mutant *hIRE1* mRNA had only 2 base changes compared to the wild-type *hIRE1* mRNA, it is expected that the reduced steady state level of *hIRE1* mRNA is a consequence of activated hIre1p kinase activity. It is possible that the expression of wild-type Ire1p is limited due to a specific
30 autoregulatory process in which the endoribonuclease activity of activated Ire1p cleaves its own mRNA, resulting in its degradation. The specific feedback on *hIRE1* mRNA suggests that the biosynthesis of hIre1p is tightly controlled. Stringent regulation of Ire1p synthesis may be necessary for cell survival as overproduction of Ire1p leads to constant activation of the UPR pathway and retardation of cell growth. Shamu, C.E., et al., *EMBO*

J. 15:3028-3039 (1996).

Although the extremely low levels of endogenous Ire1p precluded its direct visualization in mammalian cells, over-expressed wild-type Ire1p was preferentially localized to a subcompartment within the ER, with particular concentration around the nuclear envelope. In addition, a portion of hIre1p was colocalized with RanGAP1, a protein associated with the nuclear pore complex suggesting that hIre1p might be a component of the nuclear pore complex. This localization would be ideal if hIre1p-dependent RNA splicing is coupled with nucleo-cytoplasmic transport of substrate RNA molecules. In *S. cerevisiae*, the tRNA ligase, Rlg1p, mediates ligation of the *HAC1* mRNA cleaved substrate (Sidrauski, K. et al., *Cell* 90:1031-1039 (1997)) and is also localized to the nucleoplasmic side of the nuclear pore. Simos, G. et al., *EMBO J.* 15:2270-2284 (1996).

The remarkable conservation between yeast Ire1p and hIre1p functional activities suggests the existence of a human homologue to yeast *HAC1* that may exhibit selective mRNA cleavage and ligation by a human homologue of *S. cerevisiae* tRNA ligase gene *RLG1*. Furthermore, additional components of this pathway may also be conserved. For example, in *S. cerevisiae* the transcriptional co-activator complex having histone acetyltransferase activity composed of Gcn5p, Ada2p, and Ada3p is required for maximal transcriptional induction of the *KAR2* promoter. Welihinda, A.A. et al., *Proc. Natl. Acad. Sci. USA* 94:4289-4294 (1997). In addition, Ada5p, another component of this complex, is absolutely required to elicit the UPR. Welihinda, A.A. et al., *Proc. Natl. Acad. Sci. USA* 94:4289-4294 (1997). An interaction between Gcn5p and Ire1p was demonstrated (Welihinda, A.A. et al., *Proc. Natl. Acad. Sci. USA* 94:4289-4294 (1997)) and suggests that the nucleoplasmic domain of Ire1p, localized to the nuclear envelope, may serve as a nucleation site for assembly of a multisubunit transcriptional activator complex required for transcriptional activation of genes under control of the UPR. Human homologues for several of these transcriptional co-activator gene products have been identified (Candau, R. et al., *Mol. Cell. Biol.* 16:593-602 (1996)), and it is likely that these products also participate in transcriptional activation of the ER-stress responsive genes in higher eukaryotes. In addition, a Ser/Thr protein phosphatase of the PP2C gene family that is required to turn off activated Ire1p signaling in response to unfolded protein has recently been described. Welihinda, A.A. et al., *Mol. Cell. Biol.* In press (1998).

The foregoing discussion discloses and describes merely exemplary embodiments of the present invention. One skilled in the art will readily recognize from such discussion,

All patents and other publications cited herein are expressly incorporated by
5 reference.

WE CLAIM:

1. An isolated nucleic acid molecule encoding hlre1p comprising the nucleotide sequence of Figures 8A and 8B.
- 5 2. A vector comprising the nucleic acid molecule of Claim 1.
3. A cell transformed with the nucleic acid molecule of Claim 1.
4. The cell of Claim 3, wherein the cell is a mammalian cell.
- 10 5. The cell of Claim 3, wherein the cell is a bacterial cell.
6. A protein comprising a polypeptide encoded by the nucleic acid molecule of Claim 1.
- 15 7. A transfected cell producing the protein of Claim 6.
8. An antibody specific for the protein of Claim 6.
- 20 9. The antibody of Claim 8 wherein the antibody is monoclonal.
10. The antibody of Claim 8 wherein the antibody is polyclonal.
11. An isolated polynucleotide selected from the group consisting of:
 - 25 a) a polynucleotide comprising the nucleotide sequence of Figures 8A and 8B,
 - b) a polynucleotide encoding a protein comprising the amino acid sequence of Figure 9,
 - c) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of Figure 9, having biological activity,
 - 30 d) a polynucleotide which is an allelic variant of the polynucleotide of a) and,
 - e) a polynucleotide which encodes a species homologue of the protein of b) or c).
12. An isolated polynucleotide of Claim 11 wherein said polynucleotide is operably linked to an expression control sequence.

13. A host cell transformed with a polynucleotide of Claim 1.
14. The host cell of Claim 13, wherein said cell is a mammalian cell.
15. The host cell of Claim 13, wherein the cell is a bacterial cell.
16. A process for producing a protein encoded by a polynucleotide of Claim 12, which process comprises:
 - a) growing a culture of the host cell of Claim 13 in a suitable culture medium; and
 - b) purifying said protein from the culture.
17. A protein produced according to the process of Claim 16.
18. The protein of Claim 17 comprising a mature protein.
19. An isolated protein, wherein the protein comprises an amino acid sequence selected from the group consisting of:
 - a) the amino acid sequence of Figure 9, and
 - b) fragments of the amino acid sequence of Figure 9,the protein being substantially free from other mammalian proteins.
20. A cell comprising mutated hlre1p.
21. The cell of Claim 20, wherein the cell is a mammalian cell.
22. The cell of Claim 20, wherein the cell is a bacterial cell.
23. A nucleic acid probe comprising at least a fragment of a nucleic acid molecule comprising a nucleotide sequence capable of hybridizing under stringent conditions to the nucleotide sequence of Figures 8A and 8B, wherein the probe is of a length sufficient to hybridize with a complementary nucleic acid sequence thereto.
24. A method of screening a sample for a nucleic acid molecule encoding

Ire1p, wherein the sample comprises nucleic acid sequences, comprising the steps of:

- a) contacting the sample with the nucleic acid probe of Claim 23 wherein the nucleotides represented by "T" are selected from the group consisting of thymidine or uracil; and
- 5 b) detecting hybridization of the probe to complementary nucleic acid sequences encoding Ire1p in the sample.

25. A nucleic acid probe comprising at least a fragment of a nucleic acid molecule comprising a nucleotide sequence capable of hybridizing under stringent conditions to the complement of the nucleotide sequence of Figures 8A and 8B, wherein the probe is of a length sufficient to hybridize with a complementary nucleic acid sequence
5 thereto.

26. A method of screening a sample for a nucleic acid molecule encoding Ire1p, wherein the sample comprises nucleic acid sequences, comprising the steps of:

- a) contacting the sample with the nucleic acid probe of Claim 25 wherein the nucleotides represented by "T" are selected from the group consisting of thymidine or uracil; and
- 5 b) detecting hybridization of the probe to complementary nucleic acid sequences encoding Ire1p in the sample.

27. A method of increasing the survival of a cell comprising transforming the cell with the nucleotide sequence of Figures 8A and 8B.

28. The method of Claim 27, wherein said cell has been exposed to an anti-cancer treatment.

29. The method of Claim 28 wherein the anti-cancer treatment is adriamycin.

30. A method of increasing the sensitivity of a cell to death comprising inhibiting the expression of *hIRE1* in said cell.

A novel polynucleotide encoding a mammalian bifunctional protein kinase/endoribonuclease referred to herein as hlre1p, is provided. hlre1p is expressed in the endoplasmic reticulum (ER) and upregulates the transcription of genes encoding ER protein chaperones, such as, but not limited to, glucose-related proteins (GRP's). Therapeutic, diagnostic and research methods employing the polynucleotide and protein are also provided.




FIGURE 1A




FIGURE 1B

660220 622500




FIGURE 1C




FIGURE 2




FIGURE 3A




FIGURE 3C




FIGURE 3D




FIGURE 4A




FIGURE 4B




FIGURE 5

FIGURE 6A




FIGURE 6B





FIGURE 6C




FIGURE 7

FIGURE 8A

1	ccggctcgac	ggctcgggtca	ccgcctcgct	gtcgctcgcg	cgcccccggc	cgtcctctgt
61	ccgtaccgcc	cccggagcca	gggcccagtc	ctcgccatgc	cggccccggcg	gctgctgctg
121	ctgctgacgc	tgctgctgcc	cggcctcggg	atTTTTggaa	gtaccagcac	agtgacgctt
181	cctgaaacct	tgTTgtttgt	gtcaacgctg	gatggaagtt	tgcatgctgt	cagcaagagg
241	acaggctcaa	tcaaTggac	tttaaaagaa	gatccagtec	tgCaggTccc	aacacatgtg
301	gaagagcctg	cctttctccc	agatcctaT	gatggcagcc	tgtatacgct	tggaagcaag
361	aataatgaag	gcctgacgaa	acttcctttt	accatcccag	aattggtgca	ggcatcccca
421	tgccgaagtt	cagatggaat	cctctacatg	ggtaaaaaagc	aggacatctg	gtatgttatt
481	gacctcctga	ccggagagaa	gcagcagact	ttgtcatcgg	cctttgcaga	tagtctctgc
541	ccatcaacct	ctcttctgta	tcttgggcga	acagaatata	ccatcaccat	gtacgacacc
601	aaaacccgag	agtcCcggtg	gaatggccacc	tactttgact	atgcggcctc	actgcctgag
661	gacgaagggg	actacaagat	gtcccacttt	gtgtccaatg	gtgatgggct	ggTggTgact
721	gtggacagtg	aatctgggga	cgtcctgtgg	atccaaaact	acgcctcccc	tgtggTggcc
781	ttttatgtct	ggcagcggga	gggtctgagg	aaggtgatgc	acatcaatgt	cgctgtggag
841	accctgcgct	atctgacctt	catgtctggg	gaggtggggc	gcatcacaaa	gtggaagtac
901	ccgttcccca	aggagacaga	ggccaagagc	aagctgacgc	ccactctgta	tgttgggaaa
961	tactctacca	gcctctatgc	ctctccctca	atggtacacg	agggggTtgc	tgtcgtgccc
1021	cgcggcagca	cacttctttt	gctggaaggg	cccagactg	atggcgtcac	catcggggac
1081	aagggggagT	gtgtgatcac	gcccagcacg	gacgtcaagt	ttgatcccg	actcaaaagc
1141	agaacaagc	tcaactactt	gaggaattac	tggttctga	taggacacca	tgaacccca
1201	ctgtctgcgt	ctaccaagat	gctggagaga	tttcccaaca	atctacccaa	acatcgggaa
1261	aatgtgattc	ctgctgattc	agagaaaaag	agctttgagg	aagttatcaa	cctggTtgac
1321	cagacttcag	aaaacgcacc	taccaccgtg	tctcgggatg	tggaggagaa	gcccgcctat
1381	gcccctgccc	ggcccagggc	ccccgtggac	tccatgctta	aggacatggc	taccatcatc
1441	ctgagcacct	tctgtctgat	tggctgggtg	gccttcatca	tcacctatcc	cctgagcatg
1501	ctgcagcagc	agcagctcca	gcaccagcga	ttccagaagg	aactggagaa	gcagcagctc
1561	ctgcagcagc	agcagcagca	gctgcccttc	caccacctg	gagacacggc	tcaggacggc
1621	gagctcctgg	acacgtctgg	cccgtactca	gagagctcgg	gcaccagcag	ccccagcacg
1681	tccccaggg	cctccaacca	ctcgctctgc	tccggcagct	ctgcctccaa	ggctggcagc
1741	agcccctccc	tggaacaaga	cgatggagat	gaggaaacca	gcgtggTgat	agttgggaaa
1801	atttccttct	gtcccaagga	tgtcctgggc	catggagctg	agggcacaaT	tgtgtaccgg
1861	ggcatgtttg	acaaccgcga	cgtggccgtg	aagaggatcc	tccccagtg	ttttagcttc
1921	gcagaccgtg	aggtccagct	gttgcgagaa	tcggatgagc	acccgaacgt	gatccgctac
1981	ttctgcacgg	agaaggaccg	gcaattccag	tacattgcca	tcgagctgtg	tgCagccacc
2041	ctgcaagagt	atgtggagca	gaaggacttt	gcgcatctcg	gcctggagcc	catcaccttg
2101	ctgcagcaga	ccacctcggg	cctggccccc	ctccaactccc	tcaacatcgt	tcacagagac
2161	ctaaagccac	acaacatcct	catatccatg	cccaatgcac	acggcaagat	caaggccatg
2221	atctccgact	ttggcctctg	caagaagctg	gcagtgggca	gacacagttt	cagccgccga
2281	tctgggggtgc	ctggcacaga	aggctggatc	gctccagaga	tgctgagcga	agactgtaag
2341	gagaacccta	cctacacggT	ggacatcttt	tctgcaggct	gcgtctttta	ctacgtggTc
2401	tctgagggga	gccacccttt	tggcaagtcc	ctgcagcggc	aggccaacat	cctcctgggt
2461	gcctgcagcc	ttgactgctt	gcaccagag	aagcacgaag	acgtcattgc	acgagaattg
2521	atagagaaga	tgattgcgat	ggatcctcag	aaacgcccct	cagcgaacga	cgtgctcaaa
2581	cacccgTtct	tctggagcct	agagaagcag	ctccagttct	tccaggacgt	gagcgacaga
2641	atagaaaagg	aatccctgga	tggcccgatc	gtgaagcagt	tagagagagg	cgggagagcc
2701	gtggTgaaga	tggactggcg	ggagaacatc	actgaccccc	tccagacaga	cctgcgtaaa
2761	ttcaggacct	ataaaggTgg	ttctgtcaga	gatctcctcc	gagccatgag	aaataagaa
2821	caccactacc	gggagctgcc	tgCagaggtg	cgggagacgc	tggggaccct	ccccgacgac
2881	ttcgtgtgct	acttcacgtc	tcgcttcccc	cacctcctcg	cacacaccta	ccgggccatg
2941	gagctgtgca	gccacgagag	actcttccag	ccctactact	tccacgagcc	cccagagccc

FIGURE 8B

3001 cagccccag tgactccaga egccctctga gcgagggcgg cccctctgtt ctggtggccc
3061 cagctgtgac tgagggcctg gtcaccacaa ttagagcttg atgcctcccg gctttgcagg
3121 gagaccaggc ttcccaaacc aagtgccttg agctgcctgc tctgcagccc acagaggaca
3181 gtgctgaccc caggaagtgg gagaagtggc ccctcgtgac ctacagggaa ctgggaagat
3241 gctggcccca aaagccttac ggtcatgatg tctgcaaagg agggcctcag agacagcgcg
3301 agtagcacc ccagccatct actggataaa cttgcttcag actttttaaa ttcctgctta
3361 atgtcagtct acaggccttt caggaaggga gaggaggaa tcgtacattt tgcttgctg
3421 ctgggacagc taggctgaga tgcaccaagt acagccttca ctggagaccg gaattgagag
3481 gtgggggatg ctgaggagg ggaggacgga gttcagaggg tgcgtcctg cagtatgaga
3541 tttctcattg atcacagatg tgcccagagt agcccaggtc actgttaact agtgtttctg
3601 cagaggcagc aggagccagc ccggaattc

602022660

FIGURE 9

MPARRLLLLLTLLLPGLGIFGSTSTVTLPETLLFVSTLDGSLHAVSKRTGSIKWTLKEDP 60
 VLQVPPTHVEEPAFLPDPNDGSLYTLGSKNNEGLTKLPFTIPELVQASPCRSSDGILYMGK 120
 KQDIWYVIDLLTGEKQQTLSAFADSLCPSTSLLYLGRTEYTITMYDTKTRELNRWNATYF 180
 DYAASLPEDEGDYKMSHFVSNGDGLVVTVDSESGDVLWIQNYASPVVAFYVWQREGLRKV 240
 MHINVAVETLRYLTFMSGEVGRITKWKYPFPKETEAASKLTPTLYVGKYSTSLSYASPSMV 300
 HEGVAVVPRGSTLPLLEGPQTDGVTIGDKGECVITPSTDVKFDPGLKSKNKLNYLRNYWL 360
 LIGHHETPLSASTKMLERFPNNLPKHRENVIPADSEKKSFEVINLVDQTSENAPTTVSR 420
 DVEEKPAHAPARPEAPVDSMLKDMATIILSTFLLIGWVAFIITYPLSMHQQQQLQHQQFQ 480
 KELEKIQLLQQQQQQQLPFHPPGDTAQDGELLDTSGPYSESSGTSSPSTSPRASNHSLCSG 540
 SSASKAGSSPSLEQDDGDEETSVVIVGKISFCPKDVLGHGAEGTIVYRGMFDNRDVAVKR 600
 ILPECFSFADREVQLLRESDEHPNVIRYFCTEKDRQFQYIAIELCAATLQEYVEQKDFAH 660
 LGLEPITLLQQTTSGLAHLHSLNIVHRDLKPHNILISMPNAHGKIKAMISDFGLCKKLAV 720
 GRHSFSRRSGVPGTEGWIAPEMLSEDCKENPTYTVDIFSAGCVFYVYVSEGSHPFGKSLQ 780
 RQANILLGACSLDCLHPEKHEDVIARELIEKMIAMDPQKRPSANDVLKHPPFFWSLEKQLQ 840
 FFQDVSDRIEKESLDGPIVKQLERGGRAVVKMDWRENITDPLQTDLRKFRTYKGGSVRDL 900
 LRAMRNKKHHYRELPAEVRETLGTLPPDDFVCYFTSRFPHLLAHTYRAMELCSSHERLFQPY 960
 YFHEPPEPQPPVTPDAL 977

60020-22560

[illegible]

Attorney's

Docket

Number UMV-1584

Declaration, Petition and Power of Attorney for Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

IRE1P, NOVEL MAMMALIAN PROTEIN, AND GENE ENCODING SAME
the specification of which

(check one)

X is attached hereto.

was filed on _____ as _____

Application Serial No.

and was amended on _____
(if applicable)

I do not know and do not believe that the subject matter of this application was known or used by others in the United States or patented or described in a printed publication in any country before my invention thereof, or patented or described in a printed publication in any country or in public use or on sale in the United States more than one year prior to the date of this application, or first patented or caused to be patented or made the subject of an inventor's certificate by me or my legal representatives or assigns in a country foreign to the United States prior to the date of this application on an application filed more than twelve months (six months if this application is for a design) before the filing of this application; and I acknowledge my duty to disclose information of which I am aware which is material to the examination of this application, that no application for patent or inventor's certificate on the subject matter of this application has been filed by me or my representatives or assigns in any country foreign to the United States, except those identified below, and that I have reviewed and understand the contents of the specification, including the claims as amended by any amendment referred to herein.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

CLAIM OF BENEFIT OF EARLIER FOREIGN APPLICATION(S)

I hereby claim priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below, and have also identified below any foreign application(s) for patent or inventor's certificate filed by me on the same subject matter having a filing date before that of the application(s) from which priority is claimed.

Check one:

☒ no such applications have been filed.

☐ such applications have been filed as follows

EARLIEST FOREIGN APPLICATION(S), IF ANY, FILED WITHIN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

Country	Application Number	Date of Filing (month,day,year)	Priority Claimed Under 35 USC 119
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No

ALL FOREIGN APPLICATION(S), IF ANY FILED MORE THAN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

[illegible]

60/093,526
(Application Serial No.)

(Application Serial No.)

- 3 -

CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S)

I hereby claim the benefit under Title 35, United States Code, §120 of any earlier United States application(s) or PCT international application(s) designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the earlier application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date(s) of the earlier application(s) and the national or PCT international filing date of this application. As to subject matter of this application which is common to my earlier application(s), if any, described below, I do not know and do not believe that the same was known or used by others in the United States or patented or described in a printed publication in any country before my invention thereof, or patented or described in a printed publication in any country or in public use or on sale in the United States more than one year prior to the date(s) of said earlier application(s), or first patented or caused to be patented or made the subject of an inventor's certificate by me or my legal representatives or assigns in a country foreign to the United States prior to the date(s) of said earlier application(s) on an application filed more than twelve months (six months if this application is for a design) before the filing of said earlier application(s); and I acknowledge that no application for patent or inventor's certificate on said subject matter has been filed by me or my representatives or assigns in any country foreign to the United States except those identified herein.

(Application Serial No.)	(Filing Date)	(Status) (patented,pending,aband.)
--------------------------	---------------	---------------------------------------

(Application Serial No.)	(Filing Date)	(Status) (patented,pending,aband.)
--------------------------	---------------	---------------------------------------

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

W. Hugo Liepmann	Reg. No. 20,407	Catherine J. Kara	Reg. No. 41,106
James E. Cockfield	Reg. No. 19,162	Faustino A. Lichauco	Reg. No. 41,942
Thomas V. Smurzynski	Reg. No. 24,798	Jeanne M. DiGiorgio	Reg. No. 41,710
Ralph A. Loren	Reg. No. 29,325	Megan E. Williams	Reg. No. 43,270
Giulio A. DeConti, Jr.	Reg. No. 31,503	Nicholas P. Triano III	Reg. No. 36,397
Ann Lamport Hammitte	Reg. No. 34,858	Peter C. Lauro	Reg. No. 32,360
Elizabeth A. Hanley	Reg. No. 33,505	Reza Mollaaghababa	Reg. No. 43,810
Amy E. Mandragouras	Reg. No. 36,207	Timothy J. Douros	Reg. No. 41,716
John V. Bianco	Reg. No. 36,748	John L. Welch	Reg. No. 28,129
Anthony A. Laurentano	Reg. No. 38,220	DeAnn F. Smith	Reg. No. 36,683
Jane E. Remillard	Reg. No. 38,872	William D. DeVaul	Reg. No. 42,483
Jeremiah Lynch	Reg. No. 17,425	David J. Ridders	Reg. No. 43,882
Kevin J. Canning	Reg. No. 35,470		
David A. Lane, Jr.	Reg. No. 39,261		

Send Correspondence to DeAnn F. Smith at **Customer Number: 000959** whose address is:

Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109

Direct Telephone Calls to: (name and telephone number)

DeAnn F. Smith, (617) 227-7400

Wherefore I petition that letters patent be granted to me for the invention or discovery described and claimed in the attached specification and claims, and hereby subscribe my name to said specification and claims and to the foregoing declaration, power of attorney, and this petition.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor	
Randal J. Kaufman	
Inventor's signature	Date
Residence	
5065 Red Fox Run, Ann Arbor, Michigan 48105	
Citizenship	
Post Office Address (if different)	

Full name of second inventor, if any Witoon Tirasophon	
Inventor's signature	Date
Residence 1108 Malden Lane, Apt. 105, Ann Arbor, Michigan 48105	
Citizenship	
Post Office Address (if different)	

Full name of third inventor, if any Ajith A. Welihinda	
Inventor's signature	Date
Residence 2781 International Drive, #519B, Ypsilanti, Michigan 48197	
Citizenship	
Post Office Address (if different)	